Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
48°
Rain
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
128.26
-0.54 (-0.42%)
Official Closing Price
Updated: 4:10 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
January 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Via
MarketBeat
Merck Announces Second-Quarter 2023 Dividend
January 24, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
January 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
January 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
January 05, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Big Health Care Stocks to Watch in the New Year
December 29, 2022
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
Via
MarketBeat
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
December 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
December 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
December 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
December 20, 2022
From
Seagen Inc.
Via
Business Wire
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
December 15, 2022
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
December 13, 2022
Via
ACCESSWIRE
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
December 12, 2022
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
December 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2023 Dividend
November 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
November 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
November 21, 2022
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Imago BioSciences, Inc.
November 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
November 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END
Via
FinancialNewsMedia
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
November 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
November 07, 2022
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...
Via
FinancialNewsMedia
Exposures
COVID-19
Why Investors Are Suddenly Excited About Vaxcyte
October 31, 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via
MarketBeat
Exposures
COVID-19
Can Big Data Make Patient Care More Personalized And Effective?
October 28, 2022
It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets...
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.